Mutations in the gene encoding the ␥2 subunit of the ␥-aminobutyric acid type A receptor (GABRG2) have been reported to cause childhood absence epilepsy (CAE), febrile seizures (FS), and generalized epilepsy with FS plus (GEFSϩ). The authors analyzed GABRG2 in 47 unrelated patients with CAE, FS, and GEFSϩ and identified a novel mutation that cosegregated with FS. Electrophysiologic studies demonstrated altered current desensitization and reduced benzodiazepine enhancement in mutant receptors.
Febrile seizures (FS; MIM 121210) account for the majority of childhood seizure disorders, affecting 2% to 5% of children before age 5 years. FS are usually benign, but 2% to 7% of children with FS develop epilepsy later in life. In 1997, Scheffer and Berkovic described the syndrome of generalized epilepsy with FS plus (GEFSϩ; MIM 604233). 1 GEFSϩ patients have classic FS, FS that persist beyond age 5 years (FS plus, FSϩ), and subsequent afebrile seizures, including absences.
Mutations in the gene encoding the ␥2 subunit of the ␥-aminobutyric acid type A (GABA A ) receptor (GABRG2) have been described in GEFSϩ. 2, 3 The GABA A receptor is a ligand-gated chloride channel that consists of two ␣ subunits, two ␤ subunits, and one ␥ or ␦ subunit. The receptor complex contains two GABA-binding sites and a benzodiazepinebinding site. Two regions necessary for binding of benzodiazepines are present in the extracellular amino terminus of the ␥2 subunit. Electrophysiologic studies demonstrated that GEFSϩ-associated GABRG2 mutations cause accelerated current deactivation or decreased current amplitude due to reduced membrane expression of GABA A receptors. 4, 5 Identification of additional GABRG2 disease alleles and subsequent functional characterization will aid in our understanding of the contribution of GABRG2 mutations to the pathophysiology of epilepsy.
Methods. We selected 47 unrelated patients with a diagnosis of FS (n ϭ 14), GEFSϩ (n ϭ 22), or CAE (n ϭ 11) and with multiple family members with seizures. Patients and their relatives were diagnosed according to the classification criteria of the International League Against Epilepsy. 6 DNA samples were sent to our laboratory for further diagnostic genetic analysis for the known GEFSϩ genes. As a control group, 184 unrelated individuals were randomly selected from the Belgian population. The Commission for Medical Ethics of the University of Antwerp approved this study, and participants or their legal representative signed an informed consent form.
We extracted genomic DNA from peripheral blood of patients using standard methods, and PCR amplified all exons and splice site junctions of GABRG2. We sequenced PCR products using the BigDye Terminator Cycle Sequencing kit from Perkin Elmer Applied Biosystems (Foster City, CA). Sequences were analyzed on an ABI 3730 automated sequencer. We used direct sequencing for segregation analysis and pyrosequencing to analyze genomic DNA of the control individuals.
Human GABA A receptor subunits ␣1, ␤2S, and ␥2L were individually subcloned into expression vector pcDNA3.1. The ␥2L subunit R139G mutation was made using the QuikChange kit and confirmed by DNA sequencing. HEK 293T fibroblasts were cultured in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum and maintained at 37°C. Using Fugene6, cells were cotransfected with human ␣1, ␤2, ␥2L (wild-type) or ␣1, ␤2, ␥2L(R139G) (homozygous) subunit complementary DNAs (cDNAs) at a ratio of 2:2:2 g and with 1 g of pHook-1 cDNA, which was used for immunomagnetic selection. 7 Electrophysiologic recordings were made 18 to 24 hours after selection.
Cell attached or lifted whole cell recordings were obtained as described 5 at Ϫ20 mV. The chloride equilibrium potential was approximately zero. Cells were rapidly superperfused with GABA and drugs with an exchange time less than 1 millisecond. The current desensitization time course was fitted using the Levenberg-Marquardt least squares method. Only currents whose best fit had four time constants were kept for analysis. Data were represented as mean Ϯ SEM, and significance was determined using a Student's unpaired t test.
Results. We analyzed GABRG2 in 47 unrelated patients with FS, GEFSϩ, or CAE. In one patient, we identified a heterozygous c.529CϾG transversion in exon 4 of GABRG2 that cosegregated with FS according to autosomal dominant inheritance with reduced penetrance (figure 1). One mutation carrier (I.1) was symptom free; no phenocopies were present. The mutated allele was not present in 368 control chromosomes. At the protein level, the c.529CϾG transversion resulted in the substitution of a highly conserved arginine with glycine at position 139 in the mature *These authors contributed equally to this work. peptide, localized in the second benzodiazepine-binding site of the ␥2 subunit.
The proband (III.2) of this three-generational family (figure 1) was a 7-year-old girl who had her first generalized tonic-clonic FS at age 13 months and her last one at age 3.5 years. In total, she experienced 10 seizures, which were all provoked by fever. Antiepileptic drug treatment (valproic acid) was started after her second episode of FS. Her 5-year-old brother (III.3) experienced a similar onset, frequency, and presentation of generalized tonic-clonic FS. He was also treated with valproic acid. In both sib-lings, the FS had a longer duration and presented more severely before age 2 years. At 1.5 years, the brother presented once with status epilepticus during 60 minutes, which was treated with IV diazepam (DZP). Their father (II.1) had a first tonic-clonic seizure associated with fever at the age of 18 months. Later he experienced 20 to 25 additional FS, the last one at age 4 years. He was treated with antiepileptic drugs. Neither grandparents (I.1 and I.2) had a history of seizures. All patients had normal mental development and did not develop epilepsy later in life.
Currents were evoked by 2-second applications of 1 mM GABA to cell attached or "lifted" cells ( figure 2A) . The average peak current of mutant receptors was not different from that of wild-type receptors (data not shown); however, mutant receptor currents desensitized more rapidly than wild-type receptor currents. There was an increased contribution of the fast component of desensitization in mutant receptors, whereas there was no difference between the time constants ( figure 2, B and C) .
We determined the extent of benzodiazepine enhancement of wild-type and mutant receptors by applying 1 M GABA with or without 1 M DZP (figure 3A). Mutant currents had significantly reduced sensitivity to 1 M DZP relative to wild-type receptors ( figure 3B) .
To eliminate the possibility that these results were due to expression of fast desensitizing, DZP-insensitive and highly zinc-sensitive ␣␤ receptors, 8 zinc sensitivity of the mutant receptors was determined. There was no significant difference in zinc inhibition between the wild-type and mutant receptors (figure 3, C and D), confirming the presence of ␣␤␥ receptors containing the mutant ␥2(R139G).
Discussion. We analyzed GABRG2 in 47 unrelated patients with FS, GEFSϩ, or CAE and with a family history of seizures. We identified a novel mutation (p.R139G) and extended the spectrum of GABRG2 mutations that result in FS. Interestingly, the mutation produced FS only and no other epilepsy seizure types. This differs from the considerable in- trafamilial and interfamilial phenotypic variability associated with previously reported GABRG2 mutations, ranging from FS and CAE to severe myoclonic epilepsy of infancy. 2, 3, 9 However, because of the limited pedigree size in our study, it was not possible to make conclusive genotype-phenotype correlations. Segregation analysis showed that individual I.1 carried the mutation and did not present with FS, illustrating that the c.529CϾG mutation was not a fully penetrant allele. However, no parental information was available to recollect possible seizure history for individual I.1, and it cannot be excluded that he had an undocumented FS. No disease-causing GABRG2 mutations were identified in the other 46 patients, illustrating that GABRG2 does not play a major role in FS, GEFSϩ, and CAE.
We demonstrated that the ␥2(R139G) mutation incorporated into GABA A receptors and conferred altered current desensitization. The fast phase of desensitization is the primary contributor to the shape of an inhibitory postsynaptic current (IPSC). 10 Increased fast phase desensitization should result in decreased IPSC amplitude and, therefore, disinhibition leading to seizures.
The p.R139G missense mutation is localized in one of two benzodiazepine-binding sites in the ␥2 subunit. Whether the reduced sensitivity of the mutation to benzodiazepines is due to altered binding or transduction remains to be determined. show that the R139G mutation was insensitive to Zn 2ϩ inhibition, indicating that the mutant subunit was expressed on the cell surface as an ␣1␤2␥2(R139G) pentamer (n ϭ 4 for each condition). (D) The Zn 2ϩ sensitivity of the R139G mutant was not different from the wild-type receptor, indicating that the benzodiazepine insensitivity was not due to reduced expression of the mutant ␥2 subunit. *** Indicates difference from wild type (p Ͻ 0.0001).
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Unilateral malignant hypertensive retinopathy
T. Umapathi, MBBS (Singapore), FRCP (UK); and Swee-Ling Wong, MBBS (UK), BA, Singapore A 42-year-old man, whose blood pressure averaged 230/130 mm Hg, presented with right brachiofacial weakness from acute left internal watershed infarctions. Funduscopy revealed severe hypertensive changes, disc edema, arteriovenous nipping, and silver wiring, confined to right eye (figure 1). Visual acuity was normal. There was no Horner's syndrome or neck pain. Neck MR scans showed severe narrowing of left internal carotid artery, from origin to the skull base, suggestive of carotid artery dissection (figure 2). The resulting reduced blood flow protected the left retina from effects of severe hypertension. 1 Accelerated hypertension was the likely cause of carotid artery dissection. 
